Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study) (BENEFIT-CA)

5 de agosto de 2022 actualizado por: Hospital de Clinicas de Porto Alegre

Home Based Exercise for Patients With Breast or Prostate Cancer During Treatment: a Feasibility Trial (The BENEFIT-CA Study)

The purpose of this trial is to evaluate the feasibility of a home based exercise program for individuals with breast or prostate cancer patients undergoing active treatment.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This feasibility trial aims to assess a home-based exercise program, including a 3-month intervention of structured physical activity and health education for individuals with breast or prostate cancer. The main objective of this trial is to assess the adherence of cancer patients to a program of structured exercise, mixed with a health education approach, implemented and accompanied in a remote approach.

The data collection will include variables related to: (a) recruitment and retentions rates; (b) attendance to exercise sessions; (c) fatigue and quality of life levels; (d) functional capacity levels; (e) adverse events related or not to the study; (f) patient selected outcomes.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

80

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Larissa Xavier Neves da Silva, Master
  • Número de teléfono: 555133596332
  • Correo electrónico: larissaxns@gmail.com

Ubicaciones de estudio

  • Brasil
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasil, 90035-007
        • Reclutamiento
        • Hospital de Clinicas de Porto Alegre
        • Contacto:
        • Contacto:
          • Larissa Xavier Neves da Silva, MSc
          • Número de teléfono: 555133596332
          • Correo electrónico: larissaxns@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • eighteen years old minimum;
  • be living in Porto Alegre or metropolitan region;
  • breast cancer stage 0 - III OR
  • localized prostate cancer;
  • undergoing hormonal treatment / manipulation in isolation or combined with other therapies three months prior to the entrance in the study;
  • hormonal therapy / manipulation planned to be active throughout the study duration;
  • not engaged in any exercise training for more than once a week for the past 6 months;
  • in case of previous surgical procedure, the patient must have medical clearance at the moment of the contact to begin the study or be cleared to do so in the near future (up to two weeks).

Exclusion Criteria:

  • metastatic phase / progression of the disease or active regional location prior to beginning of the study;
  • inability to understand the terms and conditions of study due to language, hearing, cognitive or severe psychiatric issues;
  • another family member, who lives at the same residence, participating in the study;
  • planning to move or major absence (more than two weeks) during the study;
  • history of cardiovascular disease (except controlled hypertension) or severe cardiopulmonary disease, as well as history of heart attack, revascularization procedures, profound venous thrombosis, encephalic vascular accident (brain stroke) or pulmonary embolism in the past twelve months;
  • chronic pulmonary disease that requires oxygen or corticosteroid therapy;
  • kidney disease with or that is going to begin the use of dialysis or waiting for a kidney transplant;
  • severe nausea, anorexia or any other condition which does not allow to perform physical exercise;
  • medical contraindication to exercise training.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Home-based exercise program
This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
Otro: Home based exercise training
The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Trial adherence
Periodo de tiempo: Up to12 weeks.
Proportion of self-reported exercise episodes (out of 36 episodes, total) during the study.
Up to12 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Recruitment yields
Periodo de tiempo: Up to 8 weeks before allocation to the study intervention.
Proportion of included participants (who signed the informed consent) in relation to the total number of screened individuals for eligibility.
Up to 8 weeks before allocation to the study intervention.
Adverse events throughout the study
Periodo de tiempo: Up to 12 weeks.
Self-reported adverse events, related or not to the study. These measures will be mostly received by phone calls or text messaging.
Up to 12 weeks.

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Fatigue levels at baseline and at the end of the study
Periodo de tiempo: Baseline; Week 12.
Fatigue scores using specific questionnaires of Functional Assessment of Cancer Therapy (FACT questionnaire) for breast or prostate cancer patients.
Baseline; Week 12.
Quality of life, based on the Functional Assessment of Cancer Therapy (FACT questionnaire)
Periodo de tiempo: Baseline; Week 12.
Quality of life scores using specific questionnaires of FACT (Functional Assessment of Cancer Therapy) for breast or prostate cancer patients.
Baseline; Week 12.
Walking capacity
Periodo de tiempo: Baseline; Week 12.
Total distance (in meters) performed during the six minute walk test.
Baseline; Week 12.
Handgrip strength
Periodo de tiempo: Baseline; Week 12.
Maximum strength (in kgf) achieved by both hands in a handgrip test using a hand dynamometer.
Baseline; Week 12.
Abdominal circumference
Periodo de tiempo: Baseline; Week 12.
Anthropometric measure of the highest abdominal circumference, using a metallic measuring tape.
Baseline; Week 12.
Physical activity levels
Periodo de tiempo: Single assessment at baseline.
Physical activity calculated in minutes and intensity per week, of physical activity using the International Physical Activity Questionnaire (IPAQ).
Single assessment at baseline.
Patient selected outcomes
Periodo de tiempo: Week 12.
Through the development of the study, participants will be asked to engage in a focal group to discuss outcomes relevant to be assessed in trials with exercise interventions targeted for patients with breast or prostate cancer.
Week 12.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Hospital de Clinicas de Porto Alegre

Investigadores

  • Investigador principal: Daniel Umpierre de Moraes, PhD, Hospital de Clinicas de Porto Alegre

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de abril de 2022

Finalización primaria (Anticipado)

30 de diciembre de 2023

Finalización del estudio (Anticipado)

30 de diciembre de 2023

Fechas de registro del estudio

Enviado por primera vez

7 de febrero de 2022

Primero enviado que cumplió con los criterios de control de calidad

25 de febrero de 2022

Publicado por primera vez (Actual)

28 de febrero de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de agosto de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

5 de agosto de 2022

Última verificación

1 de agosto de 2022

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 2021-0262

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Sí

Descripción del plan IPD

Files will be as de-identified as possible before public data sharing. After data protection and data handling routines, de-identified data will be readily available to all project contributors. We consider research data gathered from data collection from research participants pertains primarily to these individuals. Therefore, all individual data will be available to their owners throughout the project. Structured data that will result from this research project will pertain to the PI (Daniel Umpierre), who will be responsible for data integrity, and to the institution (Hospital de Clinicas de Porto Alegre).

The specific structure for data sharing as well as plataforms are still to be defined. As soon, we define the remaining details of our data sharing strategy the IPD plan will be updated.

Marco de tiempo para compartir IPD

Due to space and management constraints, we are planning:

  1. To retain and store project documentation (informed consents, IRB communication, subjects' communication) for at least 10 years after the study completion (anticipated time: up to 2033).
  2. To retain and share project resources (instruments, intervention materials) as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.
  3. To retain and share datasets as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.

Criterios de acceso compartido de IPD

All the files will be password-protected and only investigators or data managers designated to use the files will be given access. Different passwords will be used for different users, which allows auditing to be made more easily. Although we do not plan to request justification to release the datasets, we do plan to share the data in a controlled approach. Therefore, once the datasets are made available at the Zenodo.org platform, only registered users will be able to download files. This procedure allows us to keep a record of data requests.

Tipo de información de apoyo para compartir IPD

  • Protocolo de estudio
  • Formulario de consentimiento informado (ICF)
  • Informe de estudio clínico (CSR)
  • Código analítico

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir